ÂÜÀòÂÒÂ×

David Neustaedter is a seasoned medical device venture capitalist currently serving as a Venture Partner at Deerfield Management since September 2022. Neustaedter holds multiple board member positions, including roles at R3 Vascular, SpectraWAVE, Inc., Presidio Medical, Inc., Deerfield Catalyst, and Reprieve Cardiovascular. Neustaedter previously served as Vice President of Venture Capital at Medtronic from July 2008 to August 2022, achieving top decile returns based on realizations. Neustaedter's academic credentials include an MBA with a concentration in Strategy from Yale School of Management, a Ph.D. in Molecular Biology from The University of British Columbia, and a B.Sc. (Honours) in Cellular, Molecular and Microbial Biology from the University of Calgary.